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Abstract: Atrial fibrillation (AF) is the most frequently encountered sustained cardiac 
arrhythmia in clinical practice and a major cause of morbidity and mortality. Effective treat-
ment of AF still remains an unmet medical need. Treatment of AF is based on drug therapy and 
ablative strategies. Antiarrhythmic drug therapy is limited by a relatively high recurrence rate 
and proarrhythmic side effects. Catheter ablation suppresses paroxysmal AF in the majority of 
patients without structural heart disease but is more difficult to achieve in patients with persis-
tent AF or with concomitant cardiac disease. Stroke is a potentially devastating complication 
of AF, requiring anticoagulation that harbors the risk of bleeding. In search of novel treatment 
modalities, targeted pharmacological treatment and gene therapy offer the potential for greater 
selectivity than conventional small-molecule or interventional approaches. This paper sum-
marizes the current understanding of molecular mechanisms underlying AF. Established drug 
therapy and interventional treatment of AF is reviewed, and emerging clinical and experimental 
therapeutic approaches are highlighted.
Keywords: atrial fibrillation, antiarrhythmic therapy, anticoagulation, catheter ablation, 
stroke
Introduction
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. The arrhyth-
mia has a prevalence of 1% and is age-dependent with ∼10% of patients .80 years 
being affected in contrast to 0.1% of all individuals ,55 years.1–3 The increasing 
epidemiological significance of AF is further illustrated by a projected calculation pre-
dicting that AF prevalence may have increased $2.5-fold by the year 2050.2 In elderly 
patients the development of AF is mostly related to cardiac disorders, whereas younger 
patients may develop AF in the absence of underlying heart disease (“lone AF”). In 
addition, gender-specific pathophysiological mechanisms are suggested by retrospective 
data. Between 1970 and 1990 the prevalence in men has more than doubled, while the 
prevalence of AF in women during this period remained unchanged. Furthermore, the 
annual incidence of AF is between 0.9% and 1.8% for men aged 65 to 74 and 1.8% 
and 4.3% for men aged 75 to 84. Corresponding incidences for women are lower and 
vary between 0.5% and 2.2% per 100 person-years, respectively.4 AF is associated 
with a 2-fold age-independent increase in mortality which is directly attributed to the 
arrhythmia as opposed to concomitant cardiovascular conditions.5
Symptoms associated with AF are primarily caused by rapid and irregular heartbeat 
and include palpitations, dizziness, lightheadedness, anxiety, and reduced exercise 
capacity which result in severely impaired quality of life.6 However, one-third of Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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patients exhibit no symptoms and are unaware of abnormal 
heart rhythm, preventing early detection and timely introduc-
tion of therapies. In a subgroup of patients the severity of 
symptoms decreases with time owing to a transition from 
paroxysmal to permanent AF.2 In predisposed individuals the 
arrhythmia may be triggered by cardiac or thoracic surgery, 
infections, alcohol intake (binge drinking; “holiday heart 
disease”), nicotine or caffeine, hypoglycemia, electrolyte 
imbalances, and physical or emotional stress.
Recent in vitro and in vivo evidence provided significant 
advances towards a comprehensive understanding of structural 
and electrical mechanisms underlying AF on the molecular 
level.7,8 Based on these data, interventional and pharmacologi-
cal therapies targeting novel mechanisms and utilizing innova-
tive modalities (eg, gene or stem cell therapy) are currently 
being developed and evaluated in pre-clinical and clinical 
studies.9,10 In the present review basic mechanistic knowledge 
is briefly summarized. We then focus on current and newly 
emerging pharmacological and interventional approaches to 
pharmacological antiarrhythmic treatment, catheter ablation, 
stroke prevention, and so-called “upstream therapy” (ie, rever-
sal of atrial remodeling by targeting substrate development).
Pathology
In recent years the pathophysiology of AF has been studied 
extensively. Two basic electrophysiological mechanisms 
are proposed to underlie initiation and perpetuation of 
AF (Figure 1). First, rapid ectopic activity may trigger 
and maintain AF.7 Second, sustained AF may depend on 
single or multiple electrical re-entrant circuits resulting 
from shortening of effective refractory periods and from 
localized deceleration of intra-atrial conduction. In addition 
to initiation by electrical trigger beats, re-entry requires a 
susceptible substrate such as fibrosis. Both mechanisms are 
not mutually exclusive. Rather, trigger activity and re-entry 
co-exist and influence each other, providing a mechanistic 
basis for the progressive nature of the disease. In addition to 
electroanatomical mechanisms, genetic mutations as well as 
several loci associated with AF have been identified through 
analysis of rare monogenetic hereditary AF or using genome-
wide association studies, respectively.11–17 Affected genes or 
regulatory elements and their pathophysiological roles are 
not yet identified in the majority of cases.
Focal electrical activity
Ectopic impulse formation is caused by localized discharges 
from electrical “pacemakers” arising from an area other 
than the sinus node. In AF, pulmonary veins exhibit elec-
trical activity that triggers the arrhythmia.18 Automaticity 
may be attributed to an imbalance of cellular repolarizing 
and depolarizing ionic currents in the diastolic phase of 
the action potential which depends on the adrenergic tone. 
If diastolic depolarization is increased, the cell reaches the 
threshold for premature action potential firing, and generates 
ectopic activity. In addition, early or delayed after depolariza-
tions (EAD or DAD) may depolarize a cell before the next 
expected normal action potential and cause premature action 
potential firing. Early after depolarization results from a pro-
longation of the action potential duration owing to reduced 
repolarizing K+ currents. Delayed after depolarizations are 
caused by spontaneous diastolic release of Ca²+ ions from 
the sarcoplasmic reticulum (SR), which may be due to SR 
calcium overload or to dysfunctional Ca²+ release through 
channels in the sarcoplasmic reticulum.
Mechanisms of re-entry
At the molecular level, re-entry may arise from two different 
pathophysiological mechanisms (Figure 1). First, re-entry 
and the development of AF may depend on the local bal-
ance between cellular refractoriness and conduction veloc-
ity (“leading circle idea”).7,8,19 If refractoriness is short and 
the intercellular transmission of action potentials is slow, 
the likelihood of circulating impulses after a distinct single 
re-entry circuit is increased. The re-entrant circuit terminates 
when the effective refractory period is prolonged or when 
impulse propagation is accelerated, forcing the excitation 
wave front into tissue that is still refractory. According to a 
Re-entry
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Figure  1  Electrical  mechanisms  of  atrial  fibrillation  (AF).  Rapid  ectopic  activity 
and re-entry are key electrophysiological mechanisms of AF. The development of 
functional re-entrant circuits requires a trigger (eg, an ectopic beat) that initiates the 
arrhythmia. Atrial remodeling creates a structural substrate for re-entry by altering 
ion channel function or by inducing fibrosis. The leading circle concept and the spiral 
wave  hypothesis  represent  models  of  re-entry.  Remodeling  may  induce  ectopic 
electrical discharges through changes in Ca²+ ion desposition or K+ current levels, 
resulting in trigger activity.
Abbreviations: eAD, early after depolarization; DAD, delayed after depolarization.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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second model (“spiral wave theory”), the re-entering wave 
front resembles a spiral or top that continuously and rapidly 
rotates around a central core.20,21 Maintenance of spiral wave 
rotor activity depends on high cellular excitability and short 
atrial refractoriness. Drifting of rotor activity across the atria 
occurs with slow rotation speed, de-stabilizing electrical and 
positional stability and promoting its termination when reach-
ing refractory tissue or anatomical boundaries.
Recent observations have suggested a more complex 
mechanism of AF, which is determined by patient-specific 
electrical and structural conditions (see below). Sources of 
ectopic activity located at the junction between the pulmo-
nary veins and the left atrium have been revealed to initiate 
and perpetuate AF. Multiple-circuit left atrial re-entry then 
leads to fibrillatory conduction. The number of re-entrant 
circuits that can be accommodated depends on left atrial 
size and on excitation wavelength determined by refrac-
tory periods. Small atrial diameters and prolonged atrial 
refractoriness limits the quantity of functional circuits and 
prevents sustained AF.
electrical remodeling
Evolving experimental and clinical evidence indicates that 
electrical and structural alterations referred to as atrial remod-
eling play an essential role in development and maintenance 
of AF. Remodeling may be caused either by concomitant car-
diovascular disease or by the arrhythmia itself. The generation 
of electrical conditions and anatomical substrates that support 
slow conduction, shortening of atrial refractory periods, and 
electrical re-entry is mechanistically relevant. Electroana-
tomical substrates allow for generation of multiple re-entrant 
circuits, providing the basis for maintenance of persistent AF 
and stabilizing the arrhythmia. Action potential shortening 
and reduced refractoriness is associated with a reduction 
of L-type Ca²+ channel expression and up-regulation of 
inward rectifier (IK1) and acetylcholine-dependent K+ current 
(IK,Ach). Spatiotemporal changes in K+ ion channel expression 
that may occur with age or in response to cardiac disease 
including AF are particularly critical.22–24 Potassium chan-
nels determine atrial action potential duration and effective 
refractory periods, and both increased and reduced K+ chan-
nel activity can lead to atrial arrhythmia. The significance 
of potassium channel dysfunction is well documented for 
ventricular arrhythmias.24,25 In addition, atrial fibrosis reduces 
conduction velocity locally, causes anisotropic conductivity, 
and represents an irreversible substrate for AF.26 Additional 
structural changes observed during AF include inflammatory 
reaction, amyloid deposit, apoptosis, necrosis, hypertrophy, 
redistribution of gap junctions, microvascular changes, and 
endocardial remodeling. The molecular mechanisms lead-
ing to electroanatomical remodeling remain incompletely 
understood.
Autonomic nervous system
Cardiac electrophysiology is tightly regulated by the 
autonomic nervous system. The delicate balance between 
adrenergic and cholinergic stimulation influences the occur-
rence and maintenance of AF.27 Adrenergic activity and 
increased catecholamine levels trigger AF acutely and are 
associated with chronic AF, while β-blockers are effective 
in suppressing the arrhythmia. Furthermore, abnormal heart 
rate variability indicating disturbances of cardiac autonomic 
regulation was identified as an independent risk factor of AF, 
and vagosympathetic nerve stimulation has proven effective 
to reduce AF and to prevent and reverse atrial remodeling 
induced by cholinergic stimulation.28,29 Electrophysiological 
effects of adrenergic and cholinergic stimuli are mediated 
via regulation of multiple cardiac ion currents, including 
pacemaker current, L-type Ca²+ current, and multiple potas-
sium ion channels.27
Treatment
Clinical classification
Atrial fibrillation tends to progress from short episodes to lon-
ger more frequent attacks and sustained forms of arrhythmia. 
Asymptomatic episodes are common, even in symptomatic 
patients. Five types of AF are clinically distinguished based 
on the duration of the arrhythmia:
1.  First diagnosed AF is present in patients who experience 
AF for the first time.
2.  Paroxysmal AF terminates spontaneously within less than 
7 days after onset.
3.  Persistent AF extends beyond 7 days or requires termina-
tion by cardioversion.
4.  Long-standing persistent AF is diagnosed when persistent 
AF lasts $1 year.
5.  The term permanent AF is used when the arrhythmia is 
accepted and no rhythm control strategy is followed.
Of note, the risk of thromboembolism does not depend 
on the duration of AF episodes. Thus, therapies aimed at pre-
venting AF-related complications (eg, stroke) are similarly 
required in all cases of AF.
Therapeutic concepts
AF therapy focuses on symptom management and prevention 
of complications and may require treatment of concomitant Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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cardiac or endocrine disease, control of cardiac rhythm and 
ventricular rate, and antithrombotic therapy (Figure 2). The 
successful treatment of primary causes is essential to sup-
press or eliminate AF. During AF, normal AV node conduc-
tion can lead to rapid ventricular rate response, resulting in 
impairment of left ventricular function and severe limitation 
of physical activity, which is a frequent cause for patient 
hospitalization. Rate control is usually achieved by pharma-
cological reduction of AV nodal conduction velocity until the 
ventricular heart rate is decreased to a less symptomatic state. 
In contrast, rhythm control aims at converting the patient’s 
heart rhythm to normal sinus rhythm (NSR) and at main-
taining NSR once achieved. Prevention of thromboembolic 
complications is a major priority and reduces morbidity and 
mortality. For patients with increased bleeding risk, surgi-
cal exclusion or interventional occlusion of the left atrial 
appendage (LAA) are available.
Current antiarrhythmic drug therapy
Conditions that increase excitability and shorten refractori-
ness promote AF maintenance. Rhythm control drugs aiming 
at suppression of AF target these mechanisms. However, the 
number of compounds available for rhythm control is limited. 
Classic antiarrhythmic Na+ current inhibitors (class I drugs) 
decrease excitability and destabilize rotator activity, while 
K+ channel blocking (or class III) drugs suppress re-entry 
mechanisms by extending action potential duration and 
repolarization. Class Ic agents increase mortality in patients 
with structural heart disease, and amiodarone harbors an 
extensive side effect profile despite its efficacy in main-
taining sinus rhythm. Nonetheless amiodarone is the most 
frequently used antiarrhythmic drug to achieve and maintain 
normal sinus rhythm. In addition, amiodarone has a heart 
rate lowering effect and simultaneously can be used for rate 
control, particularly if classic rate control agents failed or 
are contraindicated. The use of amiodarone is limited by 
significant adverse effects including decreased blood pres-
sure, pulmonary toxicity, skin discoloration, thyroid toxicity, 
corneal deposits, optic neuropathy, and sinus bradycardia. 
As a result, a significant number of patients are not eligible 
or refuse to take the drug. Furthermore, rhythm control by 
either of these compounds has not been shown to reduce 
patient mortality. Pharmacological rate control is usually 
achieved by suppression of calcium currents or by application 
of common drugs such as β-blockers or digitalis compounds. 
In a subset of AF patients, pharmacological interventions are 
not tolerated or inefficient. The remaining option in clinical 
practice is a non-specific and palliative last resort approach 
combining pacemaker implantation and AV node ablation. 
Despite representing a primary approach to pharmacological 
treatment of AF, current antiarrhythmic therapy displays low 
efficacy or harbors a poor safety profile, illustrating the need 
for novel drugs to treat AF. Consequently, pharmaceutical 
research has focused on the development of more favorable 
multichannel-blocking agents as well as novel ion-channel 
and non-channel targets.7,9
Rate vs rhythm control
Studies comparing rate and rhythm control strategies (PIAF 
[Pharmacological Intervention in Atrial Fibrillation]; 
AFFIRM [Atrial Fibrillation Follow-up Investigation of 
Rhythm Management]; RACE [Rate Control versus Electri-
cal Cardioversion for Persistent Atrial Fibrillation]; STAF 
[The Strategies of Treatment of Atrial Fibrillation], and HOT 
CAFE [How to Treat Chronic Atrial Fibrillation]) did not 
prove morbidity/mortality benefits, and rhythm control using 
the class III drug amiodarone was associated with higher 
hospitalization rates.30–34 These findings are counterintuitive 
considering severe complications and mortality associated 
with AF but may be attributed to proarrhythmic side effects 
of antiarrhythmic drugs used for rhythm control. In clinical 
practice, the decision between rate or rhythm control depends 
on multiple patient-specific factors including the severity of 
symptoms, hemodynamic effects, duration and frequency of 
rate control agents
AV node ablation
+ pacemaker
Treatment of atrial fibrillation
1. Treatment of underlying disorder
2. Prevention of thromboembolism
3. Rate control
4. Rhythm control
5. Upstream therapy
oral anticoagulants
aspirin
occlusion of LAA
antiarrhythmic drugs
catheter ablation
cardioversion
ACE inhibitors
ARBs
statins
Figure 2 Overview: treatment options for patients with atrial fibrillation.
Abbreviations: LAA, left atrial appendage; ACe, angiotensin-converting enzyme; 
ARB, angiotensin receptor blocker.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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AF episodes, underlying structural or endocrine disease, and 
the outcome of previous treatment regimes.
Acute pharmacological and direct  
current cardioversion
Many episodes of AF terminate spontaneously within 24 to 
48 hours. However, an inappropriate ventricular rate or irreg-
ular heartbeat associated with AF may require acute recovery 
of sinus rhythm in severely compromised patients. Acute 
conversion to NSR may be achieved either pharmacologically 
or by direct current cardioversion (DCC). In cases of hemo-
dynamic instability, immediate DCC should be performed. In 
stable patients with recent onset AF (within less than 7 days) 
or in patients with persisting symptoms despite adequate 
rate control, pharmacological cardioversion may be useful. 
The acute success rate of pharmacological cardioversion is 
lower compared with direct current cardioversion (DCC), but 
sedation or anesthesia is not required. For pharmacological 
cardioversion, continuous medical supervision and ECG 
monitoring are required to detect rhythm disturbances such as 
ventricular arrhythmia, sinus node arrest, or atrioventricular 
block. Drugs available for pharmacological cardioversion 
include amiodarone, flecainide, and propafenone. Class Ic 
agents such as flecainide and propafenone may be adminis-
tered intravenously or orally to terminate acute onset AF in 
stable patients. Cardioversion following amiodarone treat-
ment typically takes at least several hours. Repeated oral 
pharmacological cardioversion (“pill in the pocket”) using 
flecainide or propafenone is applicable in selected ambulatory 
patients, once safety and efficacy of this intervention have 
been established in a monitored setting.
The risk of thromboembolism associated with pharmaco-
logical or DC cardioversion requires anticoagulant therapy that 
depends on the onset of AF.1 Most patients with AF , 48 hours 
in duration can be cardioverted on low molecular weight or 
unfractionated heparin without significant risk for stroke. If AF 
onset preceded cardioversion by .48 hours transesophageal 
echocardiography may be used to rule out intracardiac thrombi 
prior to acute cardioversion.
Novel antiarrhythmic drugs
Dronedarone is a new antiarrhythmic drug that has been 
developed to provide rhythm and rate control in AF patients, 
with fewer side effects compared with amiodarone.35 
Dronedarone is chemically related to amiodarone but unlike 
amiodarone, it does not possess the iodine moieties affecting 
thyroid function. Moreover the addition of a methyl sulpho-
nyl group decreases its lipophilicity and shortens its plasma 
half-life, thought to reduce organ toxicity due to cumulative 
effects. Similar to amiodarone, dronedarone is a multichan-
nel blocker that meets criteria of all four Vaughan Williams 
anti-arrhythmic drug classes: rate-dependent inhibition of the 
rapid Na+ current (class I), alpha and beta-adrenergic receptor 
inhibition (class II), blockade of K+ outward currents as the 
main mechanism of action (class III), and blockade of slow 
Ca2+ inward currents (class IV).36–38 Action potential duration 
is prolonged, heart rate is reduced, and the risk of torsade de 
pointes arrhythmias is low. Dronedarone was approved in 
2009 based on the results of the ATHENA trial (A Placebo-
Controlled, Double-Blind, Parallel Arm Trial to Assess the 
Efficacy of Dronedarone 400 mg bid for the Prevention of 
Cardiovascular Hospitalization or Death from any Cause in 
Patients with Atrial Fibrillation/Atrial Flutter).39 Dronedarone 
significantly reduced the incidence of hospitalization due to 
cardiovascular events or death in high-risk patients with AF. 
Dronedarone represents a valuable addition to the limited 
spectrum of antiarrhythmic drugs and is currently recom-
mended in patients with paroxysmal and persistent AF to 
achieve rate and rhythm control, excluding cases of severe 
or unstable congestive heart failure. Notably, liver function 
should be closely monitored as cases of severe liver damage 
have been reported in association with dronedarone.40
In 2010 the antiarrhythmic drug vernakalant was granted 
market approval for the conversion of recent-onset AF to 
sinus rhythm.41 The antiarrhythmic agent inhibits cardiac Na+ 
and K+ channels including atrial-selective channels Kv1.5 
(IKur) and Kir3.1/Kir3.4 (IK,Ach) and prolongs atrial refracto-
riness without significantly affecting ventricular effective 
refractory periods in humans.41–43 The AVRO (A Phase III 
Superiority Study of Vernakalant vs Amiodarone in Subjects 
with Recent Onset Atrial Fibrillation) trial indicated superior-
ity of vernakalant compared with amiodarone for cardiover-
sion within 90 minutes.44 Transient dysgeusia and sneezing 
are the most common adverse events in vernakalant patients, 
and significant proarrhythmia has not been reported.
Other drugs or drug targets are currently under investigation. 
In particular, potential atrial-selective targets that have previ-
ously received little attention are now studied intensely, includ-
ing two-pore-domain potassium (K2P) or transient receptor 
potential (TRP) channels, connexins, or proteins involved in 
calcium homeostasis.9,45–48
Catheter ablation of atrial fibrillation
Catheter ablation has become an established treatment modal-
ity in symptomatic AF patients.1 Interventional strategies of 
AF ablation isolate electrical triggers inside the pulmonary Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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veins (ostial or circumferential pulmonary vein isolation), 
suppress excitation wave mobility and rotor activity by 
dividing atrial tissue into smaller, electrically isolated zones 
(creation of linear lesions), prevent re-entry and wavelet 
propagation by ablation of local areas of slow conduction 
(“complex fractionated atrial electrograms”, CFAE), or elim-
inate autonomic ganglia by ablation.18,49–52 Circumferential 
pulmonary vein isolation using irrigated radiofrequency 
current is most commonly used to isolate ectopic electrical 
PV activity from the LA. More refined techniques for cath-
eter ablation of AF are evolving rapidly to improve catheter 
manipulation, contact force monitoring, ablation efficacy, 
and procedural safety, while reducing procedure times, 
fluoroscopy exposure and physical demands. Ablation is 
currently recommended for patients with symptomatic AF 
despite antiarrhythmic treatment. Clinical presentation, left 
atrial size, previous therapy, or concomitant cardiovascular 
disease should be considered in each individual patient 
when evaluating catheter ablation.1 The recurrence rate in 
patients with paroxysmal AF is generally lower compared 
with persistent or permanent AF.53 Complications include 
pericardial tamponade, pericarditis, thromboembolic events, 
vascular complications, and pulmonary vein stenosis.2 In 
addition, esophageal injuries that depend on energy settings 
and esophageal temperature, as well as iatrogenic atrial 
septal defects caused by single-puncture, double transseptal 
approaches have been reported. Since the introduction of the 
technique the complication rate decreased while the success 
rate continuously increased owing to periprocedural safety 
measures and to improved operator skills and experience.54 
Success rates of ∼ 80% have been reported in long-term stud-
ies that included multiple ablation procedures per patient.55 
Mortality benefits of AF ablation have not yet been reported 
and are currently being investigated in a large multicenter 
trial (Catheter Ablation versus Antiarrhythmic Drug Therapy 
for Atrial Fibrillation, CABANA).56
Prevention of thromboembolic  
events in atrial fibrillation
Atrial fibrillation increases the risk of stroke, and multiple 
studies have demonstrated that oral anticoagulation with 
vitamin K antagonists (VKA) is effective and more effica-
cious than aspirin for prevention of stroke in patients with 
AF. 2,57–59 Recommendations for antithrombotic therapy are 
based on patient-specific evaluation of risk factors for stroke 
and systemic embolism. The simple CHADS2 (cardiac 
failure, hypertension, age, diabetes, and stroke [doubled])   
risk stratification scheme may be used as initial and rapid 
means of assessing the risk of embolism.58,59 A more com-
prehensive approach is offered by the CHA2DS2-VASc 
score (congestive heart failure, hypertension, age $75 
years [doubled], diabetes, history of stroke or transient 
ischemic attack [doubled], vascular disease, age 65–74, 
and sex category [female]) which considers additional risk 
factors that may be required in cases of low to moderate 
risk as assessed by CHADS2.60 Chronic oral anticoagula-
tion therapy is recommended in patients with a CHADS2 
or CHA2DS2-VASc score $2 to achieve an international 
normalized ratio (INR) value in the range of 2–3 unless con-
traindicated.1 In patient with a CHADS2 score of 0–1 addi-
tional risk stratification using the CHA2DS2-VASc scheme 
is recommended. Patients who exhibit no CHA2DS2-VASc 
risk factors may receive either no antithrombotic therapy or 
aspirin 75–325 mg daily. If one clinically relevant risk factor 
is present (CHA2DS2-VASc = 1) oral anticoagulation (OAC) 
therapy should be preferred over aspirin 75–325 mg daily. In 
all cases where OAC treatment is indicated, an assessment 
of bleeding complications is necessary to secure safety of 
OAC administration. Available risk scores that have been 
validated in anticoagulated patients include HAS-BLED 
(hypertension, abnormal renal/liver function, stroke, bleed-
ing history, labile INR, elderly [.65 years], drugs/alcohol) 
and   HEMORR2HAGES (hepatic or renal disease, ethanol 
abuse, malignancy, older [.75 years], reduced platelet 
count or function, rebleeding risk [doubled], hypertension 
[uncontrolled], anemia, genetic factors [CYP 2C9 single 
nucleotide polymorphisms], excessive fall risk, stroke).61,62 
The addition of clopidogrel to aspirin may be considered 
in patients with AF in whom OAC therapy is indicated but 
considered unsuitable.3
New anticoagulant agents
Vitamin K antagonists are cumbersome to use, require 
laboratory monitoring, and exhibit multiple interactions 
with food and drugs, resulting in significant discontinu-
ation rates. The search for new oral anticoagulant drugs 
that are effective, safe and convenient to use has focused 
primarily on direct thrombin inhibitors (eg, dabigatran) 
and factor Xa inhibitors (eg, rivaroxaban, apixaban). The 
RE-LY (Randomized Evaluation of Long-Term Anticoagu-
lant Therapy) study demonstrated non-inferiority of 110 mg 
twice a day dabigatran to VKA for prevention of stroke and 
systemic embolism with lower rates of major hemorrhage.63 
Furthermore, an increased dose (150 mg twice a day) 
exhibited lower rates of embolism and similar incidence 
of hemorrhage. Following its approval for prevention of Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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thromboembolism in AF, dabigatran may be considered as an 
alternative to VKA therapy. Recommended dosage is 150 mg 
twice a day in the US and depends on individual bleeding 
risk factors in Europe where approval is pending at the time 
of writing.1 The factor Xa inhibitor apixaban was superior to 
aspirin in AF patients intolerant or unsuitable for VKA in the 
AVERROES (Apixaban versus Acetylsalicylic Acid (ASA) 
to Prevent Strokes) trial, leading to premature termination of 
the study.64 Publication of these results is pending, and the 
non-inferiority study ARISTOTLE (Apixaban for Reduction 
in Stroke and other Thromboembolic Events in Atrial Fibril-
lation) is currently being conducted to compare apixaban to 
VKA.65 In late 2010, results of the Stroke Prevention using 
the Oral Direct Factor Xa Inhibitor Rivaroxaban Compared 
with Warfarin in Patients with Nonvalvular Atrial Fibrilla-
tion (ROCKET AF) trial were presented at the American 
Heart Association’s Scientific Sessions.66 The trial showed 
that the factor Xa inhibitor rivaroxaban was as effective as 
warfarin in preventing stroke in AF patients and did not 
increase their risk of bleeding. In the per protocol analysis, 
the rate of stroke and systemic embolism was lower in the 
rivaroxaban group than in the warfarin group, whereas in 
the intention-to-treat analysis the superiority of rivaroxaban 
over warfarin did not achieve statistical significance. These 
studies demonstrate that effective and safe alternatives to 
VKA may improve and facilitate anticoagulant therapy in 
the future.
interventional approaches  
to stroke prevention
Approximately 90% of thromboembolisms associated 
with AF are caused by thrombi originating from the left 
atrial appendage. Occlusion of the LAA should provide 
a non-pharmacological alternative to minimizing the risk 
of stroke in AF patients. However, LAA exclusion during 
surgery is not sufficiently supported by data and may even 
increase the risk of stroke if incomplete occlusion occurs, 
shifting the emphasis towards interventional strategies.67,68 
Recently, studies of percutaneous transcatheter deliv-
ery of dedicated occlusion devices (PLAATO system 
[withdrawn due to commercial reasons], WATCHMAN, 
AMPLATZER cardiac plug) have produced encouraging 
results as alternatives to VKA in selected patients.69–72 In 
particular, LAA occlusion provides a therapeutic option 
in high-risk patients with contraindications to chronic 
anticoagulation. Limitations arise from procedural com-
plications such as pericardial effusion, major bleeding, or 
device embolization.
Upstream therapy
Upstream therapy to reverse or inhibit myocardial remodeling 
associated with hypertension and heart failure may prevent 
the development of AF (primary prevention) or reduce 
recurrence rates and progression to permanent AF (second-
ary prevention). Upstream therapy is expected to reduce 
left atrial size, thereby limiting the number of functional re-
entrant circuits. In addition, upstream therapy may prevent 
re-entry by deceleration of intercellular conduction velocity 
and by suppression of electrical ion channel remodeling. 
Angiotensin-converting enzyme inhibitors, angiotensin II 
receptor blockers, and statins may be considered for primary 
prevention in patients with concomitant structural heart 
disease or for secondary prevention in cases of recurrent 
AF despite antiarrhythmic drug therapy.1,2 Evidence for 
upstream therapy for prevention of trial remodeling still 
remains controversial.
Biological antiarrhythmic therapy
Current pharmacotherapy to treat AF is limited by reduced 
efficacy, side effects, and safety issues in a significant number of 
patients. Non-pharmacological therapy is improving, but only a 
restricted number of patients can be treated by AF ablation. In 
search of novel treatment modalities, gene therapy offers greater 
selectivity than small-molecule or interventional approaches.10 
The gene of interest is commonly packaged into adenovirus 
and delivered to the target area via direct injection or catheter-
based interventional techniques, providing the advantage of 
site-restricted action in contrast to systemic application of 
drugs.10,73 Antiarrhythmic gene therapy targeting rate control 
has been evaluated in a porcine model of AF. Knock-down of 
an activating component of the adrenergic signalling pathway 
by over-expression of inhibitory G protein (Gαi2), administered 
via percutaneous access and cardiac catheterization, reduced 
mean ventricular heart rates by 15% to 25%.74,75 Gene transfer of 
the guanine nucleotide-binding proteins (GTP) binding protein 
Gem allows for control of heart rates during AF, independent 
of adrenergic signal transduction. Here AV nodal conduction is 
decreased by calcium current suppression via genetic inhibition 
of calcium channel trafficking to the plasma membrane.73 Thus, 
targeted biological modification of atrioventricular conduction 
may represent a viable strategy for heart rate control in AF. 
Biological rhythm control was achieved in a pre-clinical study 
by direct atrial gene transfer of a dominant-negative K+ chan-
nel mutant, hERG G628S.76 Inactivation of hERG channels 
results in reduced repolarizing IKr current and action potential 
prolongation and successfully suppressed pacing-induced AF 
in a porcine model.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Conclusion
Effective treatment of AF still remains an unmet medical 
need associated with high epidemiological and clinical 
relevance. Recent clinical and basic research efforts have 
revealed insights into fundamental mechanisms contributing 
to the arrhythmia. Heart diseases may induce progressive 
structural and electrical remodeling of the atria that promote 
AF by creating both substrate and electrophysiological 
properties for re-entry. After the onset of AF, atrial altera-
tions are observed within 24 to 48 hours as a consequence 
of AF. These changes are associated with reduced electrical 
conduction and shortening of effective refractory periods, 
resulting in perpetuation of the arrhythmia. Multifactorial 
etiology and pathogenesis of AF require multimodal treat-
ment of the disease, tailored to comprehensively target 
patient-specific mechanisms. The choice between frequency 
and rhythm control regimes depends on individual symptoms 
and prerequisites of each patient. Current antiarrhythmic 
drugs display either reduced efficiency or limited safety. 
Dronedarone represents a valuable addition to the limited 
spectrum of antiarrhythmic drugs and is currently recom-
mended in patients with paroxysmal and persistent AF to 
achieve rate and rhythm control, excluding cases of severe 
or unstable congestive heart failure. Catheter ablation has 
become an established treatment modality in symptomatic 
AF patients. Efforts to further refine interventional tech-
niques and to improve efficacy and safety of AF ablation are 
under way. Antithrombotic therapy is critical and should be 
based on individual risk factors for stroke/thrombembolism 
(eg, CHA2DS2-VASc score) and bleeding (eg, HAS-BLED). 
Oral compounds such as dabigatran or rivaroxaban have been 
developed to replace vitamin K antagonists and may become 
more widely available in the near future. Pharmacological 
upstream therapy using statins, angiotensin-converting 
enzyme inhibitors, or angiotensin receptor blockers could 
serve as valuable adjuvant treatment option in select cases. 
Finally, novel ion channel targets and antiarrhythmic gene 
therapy preventing substrate development and electrophysi-
ological remodeling in AF are currently established and 
evaluated in pre-clinical studies to optimize treatment of the 
most debilitating of arrhythmias.
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